BAY 794620

Drug Profile

BAY 794620

Alternative Names: 3ee9-IC; BAY-79-4620; CA9-ADC; Carboanhydrase 9 – antibody drug conjugate; MN-IC

Latest Information Update: 05 Jun 2014

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Apr 2013 Bayer completes a phase I trial for Solid tumours in the US (NCT01028755)
  • 30 Sep 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 06 Apr 2011 Pharmacodynamics data from a preclinical trial in solid tumours presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top